Funding for this research was provided by:
Belgian Federal Government
Université de Liège (Crédits Sectoriels de Recherche en Sciences de la Santé (FSR 2021))
Received: 5 August 2021
Accepted: 13 October 2021
First Online: 24 October 2021
: The study was approved by the Comité d’Ethique Hospitalo-Facultaire Universitaire de Liège (EC2021/73, March 11, 2021) and the Federal Agency for Medicines and Health Products of Belgium (EudractCT # 2021-000673-83).
: Each patient signed a written informed consent.
: Frédéric Baron has received travel grants from Celgene, Abbvie, Novartis and Sanofi as well as honoraria from Merck and Abbvie. The remaining authors declare that they have no relevant conflict of interest.